<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70691</article-id><article-id pub-id-type="doi">10.7554/eLife.70691</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-161854"><name><surname>Enrico</surname><given-names>Taylor P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241159"><name><surname>Stallaert</surname><given-names>Wayne</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241160"><name><surname>Wick</surname><given-names>Elizaveta T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241161"><name><surname>Ngoi</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-161862"><name><surname>Wang</surname><given-names>Xianxi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-81899"><name><surname>Rubin</surname><given-names>Seth M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1670-4147</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-165307"><name><surname>Brown</surname><given-names>Nicholas G</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-199085"><name><surname>Purvis</surname><given-names>Jeremy</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6963-0524</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-8323"><name><surname>Emanuele</surname><given-names>Michael J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4104-7449</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pharmacology, Lineberger Comprehensive Cancer Center</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Genetics</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Chemistry and Biochemistry</institution>, <institution>University of California, Santa Cruz</institution>, <addr-line><named-content content-type="city">Santa Cruz</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Pharmacology</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-10760"><name><surname>Hauf</surname><given-names>Silke</given-names></name><role>Reviewing editor</role><aff><institution>Virginia Tech</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>emanuele@email.unc.edu</email> (ME);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>12</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e70691</elocation-id><history><date date-type="received"><day>26</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Enrico et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Enrico et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70691-v1.pdf"/><abstract><p>Cell cycle gene expression programs fuel proliferation and are universally dysregulated in cancer. The retinoblastoma (RB)-family of proteins, RB1, RBL1/p107 and RBL2/p130, coordinately repress cell cycle gene expression, inhibiting proliferation and suppressing tumorigenesis. Phosphorylation of RB-family proteins by cyclin dependent kinases is firmly established. Like phosphorylation, ubiquitination is essential to cell cycle control, and numerous proliferative regulators, tumor suppressors, and oncoproteins are ubiquitinated. However, little is known about the role of ubiquitin signaling in controlling RB-family proteins. A systems genetics analysis of CRISPR/Cas9 screens suggested the potential regulation of the RB-network by cyclin F, a substrate recognition receptor for the SCF family of E3 ligases. We demonstrate that RBL2/p130 is a direct substrate of SCF<sup>cyclin F</sup>. We map a cyclin F regulatory site to a flexible linker in the p130 pocket domain, and show that this site mediates binding, stability, and ubiquitination. Expression of a mutant version of p130, which cannot be ubiquitinated, severely impaired proliferative capacity and cell cycle progression. Consistently, we observed reduced expression of cell cycle gene transcripts, as well a reduced abundance of cell cycle proteins, analyzed by quantitative, iterative immunofluorescent imaging. These data suggest a key role for SCF<sup>cyclin F</sup> in the CDK-RB network and raise the possibility that aberrant p130 degradation could dysregulate the cell cycle in human cancers.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM120309</award-id><principal-award-recipient><name><surname>Enrico</surname><given-names>Taylor P</given-names></name><name><surname>Wang</surname><given-names>Xianxi</given-names></name><name><surname>Emanuele</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>NIGMS,T32 GM007040</award-id><principal-award-recipient><name><surname>Enrico</surname><given-names>Taylor P</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM134231</award-id><principal-award-recipient><name><surname>Enrico</surname><given-names>Taylor P</given-names></name><name><surname>Wang</surname><given-names>Xianxi</given-names></name><name><surname>Emanuele</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R35GM128855</award-id><principal-award-recipient><name><surname>Wick</surname><given-names>Elizaveta T</given-names></name><name><surname>Brown</surname><given-names>Nicholas G</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>RSG-18-220-01-TBG</award-id><principal-award-recipient><name><surname>Enrico</surname><given-names>Taylor P</given-names></name><name><surname>Wang</surname><given-names>Xianxi</given-names></name><name><surname>Emanuele</surname><given-names>Michael J</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA163834</award-id><principal-award-recipient><name><surname>Wick</surname><given-names>Elizaveta T</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM127707</award-id><principal-award-recipient><name><surname>Ngoi</surname><given-names>Peter</given-names></name><name><surname>Rubin</surname><given-names>Seth M</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM138834</award-id><principal-award-recipient><name><surname>Stallaert</surname><given-names>Wayne</given-names></name><name><surname>Purvis</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>DP2-HD091800</award-id><principal-award-recipient><name><surname>Stallaert</surname><given-names>Wayne</given-names></name><name><surname>Purvis</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>1845796</award-id><principal-award-recipient><name><surname>Purvis</surname><given-names>Jeremy</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Unprocessed, uncropped, immunoblots are made available in the supplemental source data. All raw, unprocessed imaging data is available at Dryad. Raw data related to cell proliferation assays (cell counting and Presto-blue analysis), RT-qPCR, immunoblot quantification for cycloheximide chase experiments and flow cytometry is available in the supplemental source data.  All reagents related to this work will be made fully available upon request.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Enrico T</collab><collab>Stallaert W</collab><collab>Wick E</collab><collab>Ngoi P</collab><collab>Emanuele M</collab><collab>Rubin S</collab><collab>Brown N</collab><collab>Purvis J</collab></person-group><year iso-8601-date="2021">2021</year><source>Data from: Cyclin F drives proliferation through SCF-dependent degradation of the retinoblastoma-like tumor suppressor p130/RBL2</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.69p8cz93d">https://doi.org/10.5061/dryad.69p8cz93d</ext-link><comment>Dryad Digital Repository, doi:10.5061/dryad.69p8cz93d</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Meyers RM</collab><collab>et al</collab></person-group><year iso-8601-date="2017">2017</year><source>Cancer dependency map</source><ext-link ext-link-type="uri" xlink:href="depmap.org">depmap.org</ext-link><comment>DepMap Public 19Q3</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Dempster JM</collab><collab>Rossen J</collab><collab>Kazachkova M</collab><collab>Pan J</collab><collab>Kugener G</collab><collab>Root DE</collab><collab>Tsherniak A</collab></person-group><year iso-8601-date="2019">2019</year><source>Cancer dependency map</source><ext-link ext-link-type="uri" xlink:href="depmap.org">depmap.org</ext-link><comment>DepMap Public 19Q3</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-70691-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>